The Food and Drug Administration (FDA) has started encouraging the use of adaptive designs for clinical studies. In essence, adaptive designs allow prospectively planned modifications to a clinical trial based on interim data, provided scientific validity (the ability to draw sound inferences) and data integrity (credibility and reproducibility) are preserved.
October 18, 2017
Explore What We Learned at the 8th Clinical Quality Oversight Forum
Veristat’s Senior Director of Corporate Compliance attended the 8th Clinical Quality Oversight Forum, an annual conference which took place 10-13 October 2017 in Philadelphia, PA.